Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,177 matching trials from the live ClinicalTrials.gov search.
Conditions
HIV-1, HIV Infection
Interventions
DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 18 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
2
States / cities
Tampa, Florida • The Bronx, New York
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Transmasculine One-on-One and Group Empowerment for Targeted HIV Reduction

NCT06182280
Conditions
HIV Infections, Adherence, Medication
Interventions
PrEP4T, LS4TM
Behavioral
Lead sponsor
Fenway Community Health
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
HIV Infections
Interventions
HIV-1 Peptide Vaccine, Microparticulate Monovalent, HIV-1 Peptide Immunogen, Multivalent
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
3
States / cities
Birmingham, Alabama • Rochester, New York • Seattle, Washington
Conditions
HIV-1 Infection
Interventions
Islatravir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
4
States / cities
Hollywood, Florida • Baltimore, Maryland • Lincoln, Nebraska + 1 more
Conditions
HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities, Abnormality of Adipose Tissue, Body Weight Changes, Body Fat Disorder, HIV-Associated Lipodystrophy Syndrome
Interventions
Dolutegravir 50 MG, Antiretroviral/Anti HIV
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
HIV-1 Infection
Interventions
BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Ritonavir, GW433908
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
32
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 25 more
Conditions
HIV Infection, Infection, Human Immunodeficiency Virus
Interventions
Half-boosted Fosamprenavir, Full Boosted Fosamprenavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 39 more
Conditions
HIV Infections
Interventions
MPER-656 Liposome Vaccine, Placebo for MPER-656 Liposome Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 1 more
Completed Not applicable Interventional Accepts healthy volunteers

Contingency Management for PrEP Adherence and/or Methamphetamine Use

NCT04563962
Conditions
Methamphetamine-dependence, HIV-1-infection
Interventions
Contingency Management-ART, Contingency Management-Methamphetamine
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
HIV Infections, Pregnancy
Interventions
Lopinavir/ritonavir, Ortho Novum 1/35, Ortho Evra
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Honolulu, Hawaii + 3 more
Conditions
AIDS Vaccines, HIV Infections, HIV-1
Interventions
VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
1
States / cities
New York, New York
Conditions
HIV-1 Infection
Interventions
Not listed
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
15 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
9
States / cities
Palm Springs, California • San Diego, California • New Haven, Connecticut + 6 more
Completed Phase 1Phase 2 Interventional Results available

TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals

NCT05275998
Conditions
HIV-1-infection
Interventions
TMB-365/TMB-380
Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 3 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects

NCT01144026
Conditions
HIV Infections
Interventions
TUTI-16 (0.2mg), TUTI-16 (1.0 mg)
Biological
Lead sponsor
Thymon, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults

NCT00000904
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), gp160 MN/LAI-2, ALVAC(1)120(B,MN)GNP (vCP1433), ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Conditions
HIV Infections
Interventions
DTG film-coated tablets, DTG granules for suspension, DTG dispersible tablets
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Weeks to 17 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
17
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 11 more
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Doravirine and Weight Gain in Antiretroviral Naive

NCT05457530
Conditions
Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity, Minority Health, BMD, Metabolic Syndrome, Fasting
Interventions
DOR/3TC/TDF, DOR + FTC/TAF, BIC/FTC/TAF
Drug · Combination Product
Lead sponsor
Prism Health North Texas
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Conditions
HIV Infections
Interventions
Hydroxyurea, Nelfinavir mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
San Francisco, California
Conditions
HIV-1-infection
Interventions
EBT-101
Biological
Lead sponsor
Excision BioTherapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2037
U.S. locations
3
States / cities
San Francisco, California • St Louis, Missouri • Camden, New Jersey
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
Doravirine, 2 NRTIs, DOR/3TC/TDF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
4 Weeks to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Conditions
HIV Infections
Interventions
Treatment regimen change
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
23
States / cities
Menlo Park, California • Stanford, California • Torrance, California + 15 more
Conditions
HIV Infections
Interventions
Indinavir sulfate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more